Cargando…
Angiotensin II receptor type 1 blocker candesartan improves morphine tolerance by reducing morphine-induced inflammatory response and cellular activation of BV2 cells via the PPARγ/AMPK signaling pathway
Morphine is the most common drug of choice in clinical pain management; however, morphine tolerance presents a significant clinical challenge. The pathogenesis of morphine tolerance is known to be closely associated with angiotensin II receptor type 1 (AT1R) in microglia. As an AT1R antagonist, cand...
Autores principales: | Zhao, Wenxin, Shen, Feiyan, Yao, Jixiang, Su, Shanshan, Zhao, Zhongmin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437959/ https://www.ncbi.nlm.nih.gov/pubmed/36004465 http://dx.doi.org/10.3892/mmr.2022.12834 |
Ejemplares similares
-
Toleration of Morphine
Publicado: (1880) -
Dihydroartemisinin alleviates morphine-induced neuroinflammation in BV-2 cells
por: Guan, Sen, et al.
Publicado: (2021) -
Differential clinical profile of candesartan compared to other angiotensin receptor blockers
por: Cernes, Relu, et al.
Publicado: (2011) -
The Combination of Mitragynine and Morphine Prevents the Development of Morphine Tolerance in Mice
por: Fakurazi, Sharida, et al.
Publicado: (2013) -
Delay of Morphine Tolerance by Palmitoylethanolamide
por: Di Cesare Mannelli, Lorenzo, et al.
Publicado: (2015)